Paramita Sen

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Jean‐Charles Soria, Daniel S.W. Tan, Rita Chiari et al. · The Lancet · 2017 · 1.1K citations

Medicine, Bronchial Neoplasm, Advanced Alk +8

Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma

Eric Angevin, José A. López-Martín, Chia‐Chi Lin et al. · Clinical Cancer Research · 2013 · 129 citations

Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma

Matthew I. Milowsky, Christian Dittrich, Ignacio Durán et al. · European Journal of Cancer · 2014 · 111 citations

Urology, Genitourinary Cancer, Urothelial Carcinoma +6

Genes induced by a high-oxygen environment in Entamoeba histolytica

Md. Ali Akbar, Nabendu Sekhar Chatterjee, Paramita Sen et al. · Molecular and Biochemical Parasitology · 2003 · 78 citations

Biology, High-oxygen Environment, Extremophile +4

Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated <i>FGFR3</i>.

Matthew I. Milowsky, Christian Dittrich, Ignacio Durán Martínez et al. · Journal of Clinical Oncology · 2013 · 34 citations

Most Pts, Pathology, Tumor Biology +16